Update-5 2/10…Evommune (EVMN) up over 70% to the $29 level on Ph.2 a proof of concept trial for moderate to severe atopic dermatitis. The Company completed an IPO at $16/sh in NOV. ’25 for proceeds of $172M.
- REGN was down on the announcement but presented 36 abstracts at the AAAI Allergy Conference.Dupixent Net Global Revenues were $17.8B in 2025.
Update-4 11 a EST…PPH at $109.89 breakout confirms strength of large cap biopharma. Broad rally in overall market especially IWM offers hope for bulls.XBI up over 2% and IBBup 1.78% stops slide, but at a lower volume. Green screen developing in SMID cap trading list but look for volume on moves.
Update-3…2/5/26 2p EST….ETFs that track SMID biotechs are all down: ARKG, IBB, XBI in a risk- off market. IWM as well.
Update-2 2/4/26 It is a huge day for large cap biopharma stocks so the grid below will have to be revised at mid-FEB. The IBB was flattish at $174 because of about a 50% weighting in SMID caps. The IBB correlates with the IWM down 0.86% today.
- LLY up 10% to $1107B on Q4 REVs up 43% to $19.29B, non-GAAP EPS of $7.54 sh, Full Year , Full Year Revs 2026 Guidance of $80-83B with EPS of $33.5-$35.Full Medicare access to all obesity medicines by JY 2026, with oral weight-loss pill launch expected In Q2 2026 pending FDA approval. Market cap exceeds $1T. FWD PE of 27.
- Pfizer (PFE) rose 3.92% today carried along by the strength of the sector, good value, and by a Phase 2 long acting GLP-1. PFE has s a 6.56% dividend. PFE guided to Revs of $59.5B -62.5B with $2.80-$3.00 EPS. FWD PE is 9.41.
Update-1 2/4/26 11am-There are many earnings updates today. We will try to review them by the end of the day. Most large cap are up and doing well with the exception of Abbvie.. Update. 2/4 10:45a ..ABBV recovering to $217 level. Green screen in most other large caps. PPH up 2.57% near $109 with RSI at 63.
- ABBV stock down over 6% to $211 on earnings despite beat; non GAAP EPS $2.71, on $16.6B Revenue ,10% growth YoY Immunology revenues soar 14% to $30.4B, Neuroscience Portfolio grow 19.6% to $10.76B.
==========
Large Cap Biopharmaceuticals:Provide stable growth plus dividends.
- Large cap biopharmaceuticals provide growth plus dividends.
- Healthcare and biopharma stocks should offer some refuge from market volatility compared to tech stocks.
- M&A continues to provide growth and dynamic pipelines.
We have been consistent throughout 2025 and even earlier that Large Cap Biopharma stocks should be a core position for a healthcare equity portfolio. Now that many issues that we raised about the Trump Administrations’ criticisms about the industry, namely Pricing and U.S manufacturing have been negotiated we can look at financial metrics. Many of the large caps have commited to “reshoring” i.e investing in U.S based R&D and manufacturing in the U.S.
So here are performance metrics for January compared to previous two years. As of the end of January these values take into account the JPMorgan Health Care Conference and recent 2025 earnings updates* thru 1/31/26 with the exception of Abbvie, Amgen (2/3), LLY and Vertex (2/12)….etc.
Here are some takeaways through January 31, 2026*:
- The best performer for January was Gilead Sciences up 15% YTD and 46% over one year!
- For a value trade with turnaround potential look at Pfizer with a 6% dividend. Same for BMY.
- The sector still looks strong because ETFs beat the market: IBB up 24% over one year and PPH up 19% whereas the S&P 500 (SPY) was up only 14.37%.
- The best Mutual Fund in terms of sector continues to be Fidelity Select Biotechnology (FBIOX) up 32% over the past year.
- Here are major stock gainers over one year: GILD 46%, AZN 32%, ABBV 27%, LLY 26%, AMGN 20%.
- Still trying to decide whether to sellor buy a stock- look at the RSI as an “arbiter” Or technicals.
- JNJ (up 50% over one year) is not included in the grid because it is a Medical device and a Pharma hybrid, and it has been recently restructured,
LONG: ABBV, BMY, LLY, GILD, PFE, REGN, VRTX. Also long Swiss pharma : NVS and RHHBY.
| Analyst | p | PRICE | PRICE | * | 52 wk | |||||||||||||
| Top Biopharmas | TICKER | PICK | TECH | Fwd/PE | Summ | 2022 | 11/23 | 7/12/25 | 1/4/26 | 2/1/26 | 1 yr % | YTD | div % | RSI | high | |||
| Abbvie | ABBV | B | U/F | 15.63 | 1.84 | 161.64 | 138.59 | 192.45 | 229.31 | 223 | 27 | -2.4 | 3.02 | 51.48 | 244.8 | |||
| Amgen | AMGN | H | U | 15.45 | 2.24 | 275 | 303 | 292.27 | 327.64 | 341.88 | 20.37 | 4.45 | 2.82 | 56.1 | 253 | nh | ||
| Astra Zeneca | AZN | H/B | U | 18 | 1.63 | 68 | 63.17 | 71.13 | 91.57 | 92.77 | 32 | 0.28 | 1.69 | 50.13 | 94 | |||
| Bristol Myers Sq | BMY | B | U | 9 | 2.43 | 71.05 | 50.61 | 59 | 55.05 | 55.05 | -6.92 | 2.06 | 4.64 | 54 | 63.33 | |||
| Eli Lilly | LLY | B | U/F | 31.47 | 1.62 | 447.71 | 597.71 | 793.01 | 1080.4 | 1037 | 26 | -3.49 | 0.61 | 46.22 | 1199 | |||
| Gilead Science | GILD | H/B | U | 16.15 | 1.68 | 85.39 | 75.92 | 109.64 | 123.4 | 141.95 | 46.4 | 15.65 | 2.26 | 73.41 | 146 | nh | ||
| Merck | MRK | H/B | U | 20.93 | 1.97 | 110.95 | 103 | 106.45 | 91.45 | 110.27 | 11.44 | 4.76 | 3.14 | 67.5 | 112.9 | n/h | ||
| Pfizer | PFE | H/B | F | 8.89 | 2.39 | 51.24 | 29.48 | 25.18 | 25.87 | 26.44 | -1.75 | 6.18 | 6.59 | 60 | 27.69 | |||
| Regeneron | REGN | B | U | 14.21 | 1.73 | 725 | 798 | 567.74 | 776.3 | 741.45 | 8.55 | -3.94 | 0.51 | 44.56 | 793 | |||
| Vertex | VRTX | H/B | U | 23.65 | 1.72 | 289 | 373.65 | 468.85 | 452.13 | 469.9 | 7.19 | 3.65 | 0 | 56 | 519 | |||
| Van Eck ETF | PPH | B | U | 103.72 | 106.8 | 19.31 | 3.53 | 1.78 | 62.76 | 99.51 | LLY,NVS,MRK, NVO | |||||||
| iShares | IBB | B | F | 169 | 172.43 | 24.17 | 2.17 | 0.23 | 50.83 | 174.4 |
VRTX,GILD, AMGN REGN
|
|||||||